Abstract: The present technology is directed to implantable medical devices, systems, and methods for restricting, closing, or blocking an opening or defect in an anatomical structure. For example, many embodiments of the present technology are directed to implantable closure devices for plugging or sealing an opening in an anatomical structure separating a first body region and the second body region. In many of the embodiments described herein, the implantable closure devices are designed to be “recrossable,” such that a catheter or other percutaneous tool can be passed through the closure device after the device has been implanted.

Abstract: The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. The formulations advantageously show improved color characteristics and cause less irritation compared to other known transdermal or topica formulations comprising capsaicinoinds.

Abstract: The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous phase comprising water and at least one water soluble emulsion stabilizer; (b) an oil phase comprising at least one emulsifier, at least one oil soluble emulsion stabilizer, at least one emollient comprising at least one flavonoid and at least one other emollient; wherein the oil and aqueous phases form an emulsion; (c) an external phase comprising at least one flavonoid containing-extract, at least one phospholipid-complexed flavonoid and at least one source of berberine or analog or derivative thereof; and optionally (d) at least one preservative phase.

Abstract: The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. The formulations advantageously show improved color characteristics and cause less irritation compared to other known transdermal or topica formulations comprising capsaicinoinds.